Dr. Howard Smith Oncall

Vidcast:  https://www.instagram.com/p/C5Woz9vLkT-/ With the astronomical success of the GLP-1 agonist drugs including semaglutide and tirzepatide, shortages of these drugs are driving a search for alternatives using artificial intelligence techniques.  In addition to finding more diet drugs, the search is on for new compounds with fewer side effects. Spanish researchers are due to tell this spring’s European Congress on Obesity that their AI search of more than 10,000 naturally occurring compounds has identified two compounds that stimulate GLP-1 receptors.  These agents, dubbed Compounds A and B, are non-peptides and, as such, can be administered orally eliminating the need for injection.   Once these agents were identified, the investigators have used computer models to predict how well they will work in the human body.  More to come. https://www.medscape.com/viewarticle/ai-identifies-two-natural-bioactive-glp-1-compounds-2024a10005ze?ecd=a2a #diet #glp1agonist #semaglutide #tirzepatide #AI  diet, gl